CLINUVEL Opens VALLAURIX R&D Centre In Singapore
MELBOURNE, Australia and SINGAPORE, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research & Development Centre in Singapore, operated by CLINUVEL subsidiary VALLAURIX PTE Ltd.
- MELBOURNE, Australia and SINGAPORE, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research & Development Centre in Singapore, operated by CLINUVEL subsidiary VALLAURIX PTE Ltd.
- CLINUVEL is focused on innovative areas of medicine with VALLAURIX developing drugs from the family of melanocortins and complementary over-the-counter (OTC) consumer products.
- The new facilities will enable VALLAURIX to conduct a greater diversity of work in-house, faster and more efficiently, Dr Wright said.
- This award is offered by the Singaporean government to incentivize CLINUVEL to base its research on high values technologies in Singapore.